Plain-English translation of NCT07406217 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether immunocompromised COVID-19 patients benefit from taking nirmatrelvir/ritonavir (Paxlovid) in different ways: either alone for 5 days, alone for 10 days, or combined with another antiviral medication called remdesivir. The goal is to figure out which approach most effectively clears the virus from the body in people whose immune systems are weakened.
People with weakened immune systems often struggle to clear COVID-19 on their own, and the standard treatment may not work as well for them. Researchers want to find out if using more medication, longer treatment, or different combinations can help these vulnerable patients recover better.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of four groups: taking one medication for 5 days, the same medication for 10 days, or that medication combined with a second drug for 5 days. You would take pills by mouth as directed, and return for a follow-up visit around day 10 to have a nasal swab test done to see if the virus is still present. The entire study lasts about 10 days.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Switzerland